SBIR/STTR Research Award

A new hemagglutination method for blood grouping

Award identifier fd79ae59faf94a963b21c1c8446e0f21a54d215d68e9712a35aea0747952dc45Awarding agency Department of Health and Human Services · National Institutes of Health

Award amount

$954,976

Program and phase

SBIR · Phase II

Award year

2015

Explore This Research Award in CaptureIQ

Research the technology, evaluate the recipient and agency, identify related opportunities, and explore potential follow-on work with CaptureIQ.

Award details

Awarding agency
Department of Health and Human Services
Branch
National Institutes of Health
Recipient company
ALLIED INNOVATIVE SYSTEMS
Proposal award date
2015-09-01
Contract end date
2019-04-30
UEI
SFFKG8THUH55
Solicitation number
PA14-071
Topic code
NHLBI

Research abstract

DESCRIPTION provided by applicant The long term goal of the proposed research is to develop a novel quantitative particle agglutination technology for improving the performance of blood typing assays The conventional hemagglutination blood typing assays have serious drawbacks such as limited sensitivity long time of incubation subjectivity and large amount of reagents It is in this context that we propose to develop a new technology which is free from the aforementioned limitations of the conventional hemagglutination assays The proposed immunoassay is a sensitive and rapid method that utilizes inexpensive instrumentation The Specific Aims of Phase II are To further explore all variables affecting the performance of the new blood typing detection assays and optimize the performance of the assay To design and assemble an rototype of the device for performing of several blood typing assays simultaneously The rototype is intended to test the design of every technical element of the system before it is implemented in the final pre production prototype To validate the detection assays for determination of blood groups including weak D group and C c E e and K antigens and expected antibodies reverse typing To examine a statistically significant number of clinical samples for each assay and carry out statistical analysis and demonstrate reproducibility of the obtained results To compare performance of the conventional and newly developed assays Significantly the new method presents a general approach for enhancement and detection of agglutination of particles of different origin including latex silic microparticles and biological cells PUBLIC HEALTH RELEVANCE The development of this method will allow one to obtain quantitative results increase the sensitivity of red blood cell agglutination assays and reduce time of analysis without compromising the cost per test Successful completion of these studies will result in a substantial business opportunity to license the technology and manufacture commercial products which will be beneficial for public health

Technology keywords

Not reported

Other awards by this recipient

Verified by the same UEI. These are other public SBIR/STTR award pages, not a merged company record.

Awards with the same topic code

Verified by an exact topic code match. This is not a text-similarity match.

Research funding history

21 SBIR/STTR records share this UEI (2000–2023). Reported award amounts total $10,630,804. Reported amounts are not federal obligations.

Phases: Phase I, Phase II

Agencies: Department of Health and Human Services

Agency intelligence

Department of Health and Human Services

Back to SBIR/STTR Research Awards

Don't take our word for it. Ask AI about RFPCapture.

See what leading AI assistants have to say about RFPCapture and CaptureIQ.

Gemini opens without a prefilled question. The question is copied to your clipboard when the button works. You can also copy it here:

What is RFPCapture.com and its CaptureIQ platform from Smart Logic AI? How does it help federal contractors discover opportunities, evaluate bid/no-bid decisions, research government contracts, and prepare proposals? How does it compare with other federal capture platforms? Use independent sources where available.